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The effects of gonadotrophin releasing hormone analogues in prostate
cancer are mediated through specific tumour receptors
A. Qayuml, W. Gullick2, R.C. Clayton3, K. Sikora' & J. Waxman'
'Department ofClinical Oncology and 2ICRF Oncology Group, Royal Postgraduate Medical School, and 3Clinical Endocrinology,
MRC, Northwick Park Hospital, London, UK.
Summary We have investigated the possibility of a direct regulatory effect of gonadotrophin releasing
hormone (GnRH) analogues on prostatic cancer cell growth. Here we report high affinity binding
(Kd = 50 nM) of a GnRH analogue resulting in biphasic growth modulation of the human androgen-sensitive
prostatic cancer cell line LNCaP. In contrast, the human androgen-insensitive prostatic cancer cell line DU145
showed low-affinity (Kd= 10 M) binding without any biological response to the GnRH analogue. A GnRH-
specific radioimmunoassay demonstrated GnRH-like immunoreactivity in the concentrated culture medium
from both cell lines. Seventy-six human benign and malignant tumours were assayed following surgical
resection. Nineteen of 22 (86%) malignant tumours and 49 of 54 (91%) benign tumours, exhibited high affinity
GnRH-analogue binding. Fourteen of 19 (74%) malignant tumours and 17 of 49 (35%) benign tumours
exhibiting high affinity binding contained GnRH-like immunoreactivity, suggesting that this system may be
involved in prostatic epithelial cell growth in vivo.
Cancer of the prostate is the second most common cause of
malignancy among males. The treatment of prostatic cancer
aims to reduce serum androgen concentrations. The long-
acting agonist analogues of GnRH have been recently intro-
duced as effective alternative therapies to orchiectomy and
oestrogen treatment (Waxman, 1987). Their effect on andro-
gen dependent cell growth is thought to be mediated through
down-regulation of the pituitary-gonadal axis. GnRH agon-
ist treatment leads to an initial increase in the serum levels of
LH, FSH and androgens and this may be accompanied by
tumour flare (Waxman et al., 1985). However, this exacerba-
tion of symptoms is not temporally related to changes in
serum LH, FSH and androgen concentrations. The differ-
ences in the timing of these biochemical and clinical
phenomena raises the possibility of a direct effect of GnRH
analogues at the level of the tumour.
This present study explored the direct effects of GnRH
analogues on prostatic cancer cells in culture and in vivo.
GnRH analogue binding to human prostatic cancer cells
grown in culture and biopsy samples was first examined.
GnRH binding sites were characterised in cell lines and in
human tumours. The biological effects of GnRH on prostatic
cancer cells and a possible autocrine stimulatory role of
GnRH-like peptides were investigated.
Materials and methods
Cell culture
The human androgen-sensitive prostatic cancer cell line
LNCaP (isolated from lymph node metastasis; Horoszewicz
et al., 1983) and the human androgen-insensitive prostatic
cell line DU145 (isolated from brain metastasis) were
obtained from the American Type Culture Collection. Cul-
tures were maintained in exponential growth in RPMI 1640
medium containing 10% charcoal stripped fetal calf serum
and 5 fig ml-I insulin. The fetal calf serum used in cell cul-
ture medium was treated with dextran and charcoal to
remove steroids. Charcoal 0.25% and dextran-T70 0.025%
were added to the serum, which was heated at 56'C for 2 h
and then centrifuged at 4,000 r.p.m. for Omin. The pellet
was discarded, serum was filtered through 0.4ltm filters and
used in culture medium. The treated serum was assayed for
steroid hormones by the Hammersmith Hospital Endocrine
Laboratories and found to be steroid free, Cultures were
incubated at 37°C in a humidified atmosphere containing 5%
CO2 and subcultured weekly using 0.1% EDTA to remove
the cells from the plastic substratum. Under these conditions,
the doubling times of DU145 and LNCaP cells were 72 and
144 h respectively.
GnRHbinding assays
Exponentially growing cells were harvested with 0.1%
EDTA, washed twice with PBS and counted using 0.2%
trypan blue as an indicator. The cells were then resuspended
in assay buffer (10 mM Tris-HCI pH 7.6, 1 mM dithiothreitol,
0.3% bovine serum albumin). One million cells per tube were
incubated with 200,000 c.p.m. (0.1 nM) of 25I buserelin (125J_
D-Ser (TBU)6-LHRH-ethylamide) (Hoechst AG, Frankfurt),
(specific activity 53,000kBq;bg-') with or without varying
concentrations of unlabelled buserelin (O.1-100 nM). Non-
specific binding was estimated in the presence of 10IM
unlabelled buserelin. After 3 h incubation at 4°C, 1 ml of
ice-cold assay buffer was added and the tubes were immed-
iately centrifuged at 2,000 g for Omin. The supernatants
were discarded and the pellets were washed once with ice-
cold assay buffer and counted in a gamma counter. The
optimal time and temperature dependence of GnRH ana-
logue binding was determined in both cell lines.
Preparation of tumour cell membranes and cytosolicfractions
After transurethral resection prostatic biopsy specimens were
immediately frozen at - 70C, and subsequently cleaned and
homogenised in PBS using an Ultraturrex homogenizer
(Janke and Kunkel IKA Labortechnik, FR Germany) for
three periods of 30 s each with an interval of 3 min on ice
between each treatment. The debris and nuclear material
were removed by centrifuging twice at 2,000 g for Omin,
discarding the pellet each time. The resultant supernatants
were centrifuged at 10,000 g for 30min at 4°C. The pellets
were resuspended in PBS and either used immediately for
binding experiments or stored frozen at - 70°C. The super-
natants were stored frozen at - 70C until use. The protein
content was determined by Bradford's method (Bradford,
1976). Two hundred iLg of membrane proteins per tube were
used to assess the amount of 1251-buserelin binding.
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Biological response studies
Exponentially growing cells were harvested using 0.1%
EDTA, counted with 0.2% trypan blue and washed once
with PBS. One million cells per flask were seeded in T-25
flasks in 5 ml of RPMI 1640 medium containing 10% char-
coal stripped fetal calf serum. Fresh medium containing
various concentrations of buserelin with or without a 100-
fold excess of the GnRH antagonist D-pGlul, D-Phe2, D-
Trp3'6) GnRH (Sigma, UK) was added every third day. After
10 days the cells were harvested with 0.1% EDTA, washed
once with PBS and counted with 0.2% trypan blue. Total
DNA was estimated by Burton's method (Burton, 1956).
GnRH radioimmunoassay
The cells were cultured in RPMI 1640 medium containing
10% charcoal stripped fetal calf serum. The medium was
collected after 2 weeks, without refeeding, acidified with
0.1% trifluoroacetic acid and centrifuged at 5,000g for
10 min. The pellet was discarded and the supernatant was
passed through C-18 Sep-Pak cartridge (Millipore, UK) (pre-
wetted with methanol) followed by acidified water. The re-
tained portion was eluted with 60% acetonitrile in water.
There was 70% recovery of a control solution of buserelin
added to fresh culture medium after a similar extraction
procedure. The cytosol preparations from human prostatic
samples were similarly concentrated. The eluates were exam-
ined for GnRH-like activity using GnRH radioimmunoassay
kit (Amersham, UK). The sensitivity of the assay was
0.25 fmol per tube, inter-assay variation 7% and intra-assay
variation 12%. Bradykinin, oxytocin, TRH, concentrated
culture medium containing 10% dextran-charcoal heat-inact-
ivated FCS and concentrated culture medium containing
10% normal FCS did not show any GnRH-immunoreactivity
under the same conditions (Figure 1).
Results
GnRH receptor expression in prostatic cancer cell lines
'251-buserelin binding to membrane preparations from both
prostatic cell lines is shown in Figure 2. The LNCaP cells
showed high affinity binding of buserelin with 50% inhibition
obtained at 50 nM concentration of unlabelled peptide. The
binding was saturable and specific as the structurally
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Figure 2 Binding of '25I-GnRH analogue to LNCaP (@) and
DUI45 (0) cells (specifically bound (B): maximum bound (BO)
ratio x 100 on y axis) as a function of ligand concentration
(Buserelin log M on x axis). The binding assays were carried out
as described in Materials and methods. The results are expressed
as the mean±s.e.m. of triplicate measurements from a represen-
tative experiment. The Kd of GnRH analogue binding in LNCaP
was 50 nM, while that of DU145 cells 10 was ylM.
unrelated peptides bradykinin, oxytocin and TRH did not
displace labelled buserelin in binding assays. A Scatchard
plot of the same data indicated a single class of binding sites
with Kd = 40 nM (Figure 3). The binding of buserelin to
DUI45 cells was inhibited only by very high concentrations
of unlabelled buserelin (Kd = 10 M) indicating the presence
of only very low affinity binding sites in these cells. The
difference in specific binding of buserelin to both cell lines
was more evident when a protease substrate (L-cystine-bis-(4-
nitroanilide)) was included in the binding assays. This pro-
tease substrate has been shown to compete with GnRH for
GnRH-degrading sites (Kuhl & Baumann, 1981; Kuhl &
Taubert, 1975). The addition of this protease substrate to the
assay tubes in a final concentration of 10 gsM reduced the
specific binding by 68% in DU145 but by only 28% in
LNCaP cells (Figure 4).
The biological effect ofbuserelin on prostatic cancer cells
Treatment of LNCaP cells with buserelin for 10 days stimu-
lated the growth of the cells by as much as 140% relative to
the control cultures as measured both by cell numbers and
total DNA content (Figure 5). This stimulatory effect was
observed only at lower concentrations of buserelin (1-10 nM)
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Figure 1 GnRH-like activity detected from culture medium of
LNCaP cells. The cells were cultured for two weeks and culture
medium was concentrated as described in Materials and
Methods. Culture medium containing 10% normal FCS (3), cul-
ture medium containing 10% dextran-charcoal treated heat-
inactivated FCS (4), bradykinin (5), oxytocin (6) and TRH (7)
did not show any GnRH-immunoreactivity in GnRH-RIA. The
concentrated culture media from 2 (1) and 20 (2) million LNCaP
cells showed the presence of 3 and 30 fmol of GnRH-like activity.
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Figure 3 Scatchard transformation of the same data shown in
Figure I (the ratio of bound buserelin (B) to free buserelin (F) is
on the y axis and bound buserelin in fmol is on the x axis)
revealed that buserelin binds to a single class of binding sites in
LNCaP cells of moderately high affinity (Kd =40 nM, 35,000
binding sites per cell).
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Figure 4 Specific binding of labelled buserelin (L-, D-) was
decreased to 680% and (L +, D + ) 28% in LNCaP (L) and
DU145 (D) cells respectively when 1OIM protease substrate was
added to the assay tubes. Specific binding in the absence of
protease substrate was taken as 100%. Non-specific binding was
determined in the presence of lOpM unlabelled buserelin.
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Figure 5 Effect of buserelin treatment of LNCaP (circles) and
DU145 (triangles) cells in culture. The cells were cultured and
treated as described in Materials and methods. The cell number
(open symbols) and total DNA content (filled symbols) has been
expressed as percent of control and plotted as a function of
buserelin concentration. Each point represents ± s.e.m. of three
experiments each in triplicate.
which correlated well with the measured binding affinity. The
growth of the cells was slightly inhibited at higher concentra-
tions of GnRH analogue (100 nM). The androgen-insensitive
cells did not show any response to buserelin treatment. No
effects on cell growth were seen in short term culture. The
stimulatory and inhibitory effects of buserelin on androgen-
sensitive LNCaP cells were partially blocked when 100-fold
excess of GnRH-antagonist was added to the culture medium
(Figure 6).
Prostatic cancer cells secrete GnRH-like material
The observation that GnRH binding resulted in growth
stimulation raised the possibility of the secretion of GnRH-
like peptides by LNCaP cells themselves. We therefore exam-
ined this using a specific radioimmunoassay. The GnRH
radioimmunoassay detected GnRH-like immunoreactivity in
concentrated medium collected after two weeks culture of
both cell lines. The concentrated culture media from 2 and 20
million LNCaP cells showed the presence of 3 and 30 fmol of
GnRH-like immunoreactivity respectively (Figure 1). Twenty
million DU145 cells cultured for 2 weeks secreted 35 fmol
GnRH-like immunoreactivity. The elution profile of this
immunoreactive peptide on high performance liquid
chromatography was identical to native GnRH.
Concentration (log M)
Figure 6 The effect of the GnRH antagonist on buserelin-
induced growth modulation in LNCaP cells. The cells were cul-
tured and treated with indicated concentrations of buserelin with
or without a 100-fold excess of GnRH antagonist. The cell
numbers have been expressed as per cent of control and plotted
as function of buserelin concentration. Each point represents ±
s.e.m. of triplicate from a representative experiment. U, buserelin
only; 0, antagonist only; A buserelin + antagonist.
GnRH receptors and GnRH immunoreactive peptides are
present in prostatic biopsy specimens
GnRH analogue binding was assessed on membrane prepara-
tions from 76 benign and malignant prostate tumours. Forty-
nine of 54 (91%) benign tumours exhibited high affinity
binding (Kd = 46 ± 43 nM, capacity 390 ± 218 fmol mg- '
protein) and 19 of 22 (86%) malignant tumours showed high
affinity binding (Kd = 10 ± 14 nM, capacity 301 ± 180 fmol
mg-' protein). The GnRH radioimmunoassay showed
GnRH-like peptides to be present in 17 of 49 (35%) benign
tumours exhibiting high affinity ligand binding sites, but in
none without binding. Fourteen of 19 (74%) malignant
tumours having high affinity ligand binding sites and two of
three showing no ligand binding contained GnRH-lilke pep-
tides (Table I). The elution profile on high performance
liquid chromatography of this peptide was identical to native
GnRH.
Discussion
Extrapituitary receptors for GnRH have been described in
normal testis and ovary (Clayton et al., 1979, 1980). There
have also been reports of the presence of GnRH-binding sites
in breast cancer cells (Eidne et al., 1987), pancreatic tumours
(Szende et al., 1989) and induced rat prostatic cancers
(Kadar et al., 1988). The binding of GnRH to breast cancer
cells has been shown to result in growth modulation (Millar
et al., 1985; Eidne et al., 1987). In this present study the
observation of high affinity binding sites in prostatic cancer
cell lines and prostatic biopsy specimens suggests that GnRH
and its analogues may exert their effects directly on tumour
tissue. However, the biological effect observed in short term
culture at therapeutic concentrations (1-IO nM) of GnRH
analogue is stimulation of growth rather than inhibition. The
initial direct stimulatory effect of GnRH analogues on pros-
tatic cancer cells may therefore explain the lack of a temporal
correlation of hormonal change with the clinical observation
of tumour flare. It is possible that the long-term and con-
tinued occupancy of its binding sites by GnRH-analogues
leads to desensitisation and down-regulation of receptors
resulting in growth inhibition.
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TableI Fresh frozen, transurethrally resected benign andmalignant prostatic tissuesexamined forGnRH
binding
GnRH
activity
Capacity GnRH-RIA GnRH-RIA fmolg'
No. Kdx 10-9M (fmolmg') + ve - ve tissue
Benign prostatic hypertrophy
GnRH-R + ve 49/54 46±43 390±218 32/49 17/49 26.16±20.2
(90%) - - (65.5%) (34.7%)
GnRH-R - ve 5/54 5/5 0/5 33.12±24.1
(9.2%) (100%)
Prostatic cancer
GnRH-R + ve 19/22 10±14 301 180 5/19 14/19 77±71.4
(85%) (26.3%) (73/7%)
GnRH-R -ve 3/22 - - 1/3 2/3 100
(13.6%) (33.3%) (66.6%)
The cytosolic preparations from tissues were concentrated and assayed for GnRH-like activity in
GnRH-RIA. Results are summarised from 76 prostatic tissues.
The finding of specific GnRH-binding sites in prostatic
cancer cells which modulate growth, and the observation of
the secretion of GnRH-like peptides by these cells, suggests
that GnRH-like peptides may play an autocrine stimulatory
role in this system. It is not yet known whether GnRH itself
has mitogenic activity nor whether it has synergy with other
stimulatory growth factors, and this requires further investi-
gations. The results of our study provide impetus for the
development of GnRH antagonists for use in prostatic cancer
treatment.
We thank Dr J. Sandow (Hoechst AG, Frankfurt) for the gift of
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